Bevacizumab-Induced Reversible Thrombocytopenia in a Patient with Adenocarcinoma of Colon: Rare Adverse Effect of Bevacizumab
We report a case of bevacizumab- (BEV-) induced thrombocytopenia in a 59-year-old man with adenocarcinoma of colon. After colectomy, the patient was treated with twelve cycles of FOLFOX-4 (folinic acid, 5-fluorouracil, and oxaliplatin) regimen. On relapse, he was treated with FOLFIRI (folinic acid,...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Case Reports in Oncological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2012/695430 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832550741801172992 |
|---|---|
| author | Jeevan Kumar Manorama Bhargava Shyam Aggarwal |
| author_facet | Jeevan Kumar Manorama Bhargava Shyam Aggarwal |
| author_sort | Jeevan Kumar |
| collection | DOAJ |
| description | We report a case of bevacizumab- (BEV-) induced thrombocytopenia in a 59-year-old man with adenocarcinoma of colon. After colectomy, the patient was treated with twelve cycles of FOLFOX-4 (folinic acid, 5-fluorouracil, and oxaliplatin) regimen. On relapse, he was treated with FOLFIRI (folinic acid, 5-fluorouracil, and irinotecan) regimen along with BEV 10 mg/kg for 6 cycles. After that, BEV was continued for maintenance as a single agent at an interval of three weeks. After the13th cycle of BEV, the patient developed melena with epistaxis and thrombocytopenia, from which he recovered on withdrawal of BEV. On rechallenge with half the initial dose, there was once again a reversible drop in platelet count. The proposed mechanism of thrombocytopenia may be immune-mediated peripheral destruction of platelets. |
| format | Article |
| id | doaj-art-0e5b58d27771452297ad0b72b8ce6020 |
| institution | Kabale University |
| issn | 2090-6706 2090-6714 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Oncological Medicine |
| spelling | doaj-art-0e5b58d27771452297ad0b72b8ce60202025-02-03T06:05:52ZengWileyCase Reports in Oncological Medicine2090-67062090-67142012-01-01201210.1155/2012/695430695430Bevacizumab-Induced Reversible Thrombocytopenia in a Patient with Adenocarcinoma of Colon: Rare Adverse Effect of BevacizumabJeevan Kumar0Manorama Bhargava1Shyam Aggarwal2Sir Ganga Ram Hospital, New Delhi 110060, IndiaSir Ganga Ram Hospital, New Delhi 110060, IndiaSir Ganga Ram Hospital, New Delhi 110060, IndiaWe report a case of bevacizumab- (BEV-) induced thrombocytopenia in a 59-year-old man with adenocarcinoma of colon. After colectomy, the patient was treated with twelve cycles of FOLFOX-4 (folinic acid, 5-fluorouracil, and oxaliplatin) regimen. On relapse, he was treated with FOLFIRI (folinic acid, 5-fluorouracil, and irinotecan) regimen along with BEV 10 mg/kg for 6 cycles. After that, BEV was continued for maintenance as a single agent at an interval of three weeks. After the13th cycle of BEV, the patient developed melena with epistaxis and thrombocytopenia, from which he recovered on withdrawal of BEV. On rechallenge with half the initial dose, there was once again a reversible drop in platelet count. The proposed mechanism of thrombocytopenia may be immune-mediated peripheral destruction of platelets.http://dx.doi.org/10.1155/2012/695430 |
| spellingShingle | Jeevan Kumar Manorama Bhargava Shyam Aggarwal Bevacizumab-Induced Reversible Thrombocytopenia in a Patient with Adenocarcinoma of Colon: Rare Adverse Effect of Bevacizumab Case Reports in Oncological Medicine |
| title | Bevacizumab-Induced Reversible Thrombocytopenia in a Patient with Adenocarcinoma of Colon: Rare Adverse Effect of Bevacizumab |
| title_full | Bevacizumab-Induced Reversible Thrombocytopenia in a Patient with Adenocarcinoma of Colon: Rare Adverse Effect of Bevacizumab |
| title_fullStr | Bevacizumab-Induced Reversible Thrombocytopenia in a Patient with Adenocarcinoma of Colon: Rare Adverse Effect of Bevacizumab |
| title_full_unstemmed | Bevacizumab-Induced Reversible Thrombocytopenia in a Patient with Adenocarcinoma of Colon: Rare Adverse Effect of Bevacizumab |
| title_short | Bevacizumab-Induced Reversible Thrombocytopenia in a Patient with Adenocarcinoma of Colon: Rare Adverse Effect of Bevacizumab |
| title_sort | bevacizumab induced reversible thrombocytopenia in a patient with adenocarcinoma of colon rare adverse effect of bevacizumab |
| url | http://dx.doi.org/10.1155/2012/695430 |
| work_keys_str_mv | AT jeevankumar bevacizumabinducedreversiblethrombocytopeniainapatientwithadenocarcinomaofcolonrareadverseeffectofbevacizumab AT manoramabhargava bevacizumabinducedreversiblethrombocytopeniainapatientwithadenocarcinomaofcolonrareadverseeffectofbevacizumab AT shyamaggarwal bevacizumabinducedreversiblethrombocytopeniainapatientwithadenocarcinomaofcolonrareadverseeffectofbevacizumab |